Sustained clinical benefit seen in patients treated with ADXS-503 in combination with  KEYTRUDA®  after 16 weeks, including a partial response and stable disease in patients who had most recently progressed on  KEYTRUDA® Positive preliminary immunogenicity data with CD8+ T cells generated in all of

PRINCETON, N.J. , March 13, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced an update on its clinical pipeline and financial results for the first quarter ended

PRINCETON, N.J., March 03, 2020 (GLOBE NEWSWIRE) --  Advaxis, Inc. (Nasdaq: ADXS) , a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis will

First two patients treated in the combination arm who previously progressed on  KEYTRUDA®  showed substantial tumor shrinkage with ADXS-503 treatment in combination with  KEYTRUDA® Partial response observed in one patient and the other patient achieved stable disease with a 25% reduction in a

ADXS-503 safe and tolerable with potential signs of clinical activity in 4 of 7 evaluable patients achieving stable disease in the refractory setting Patient who previously progressed on pembrolizumab showed stable disease with a 25% reduction in a site lesion in combination arm PRINCETON,

Median overall survival of 16.4 months for advanced prostate cancer patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA ®  compared to an estimated 11 months with Standard of Care Median overall survival of 33.7 months in all patients treated with ADXS-PSA in

PRINCETON, N.J. and MENLO PARK, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer,

PRINCETON, N.J., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the following upcoming presentations at medical meetings: ASCO - Genitourinary Cancers

PRINCETON, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) --  Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into a definitive agreement with two institutional

ADXS-504 is the Company’s second drug product candidate from the HOT program to receive IND clearance from FDA PRINCETON, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy